Spyre Therapeutics (SYRE) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Spyre Therapeutics (SYRE) over the last 6 years, with Q3 2025 value amounting to -$0.15.
- Spyre Therapeutics' EPS (Weighted Average and Diluted) rose 9964.49% to -$0.15 in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.77, marking a year-over-year increase of 9503.27%. This contributed to the annual value of -$4.42 for FY2024, which is 9919.62% up from last year.
- Per Spyre Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.15 for Q3 2025, which was up 9964.49% from $22.86 recorded in Q2 2025.
- Spyre Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $40.14 during Q2 2023, with a 5-year trough of -$564.94 in Q4 2023.
- Over the past 5 years, Spyre Therapeutics' median EPS (Weighted Average and Diluted) value was -$2.94 (recorded in 2022), while the average stood at -$36.72.
- The largest annual percentage gain for Spyre Therapeutics' EPS (Weighted Average and Diluted) in the last 5 years was 1496666.67% (2023), contrasted with its biggest fall of 1194562.9% (2023).
- Quarter analysis of 5 years shows Spyre Therapeutics' EPS (Weighted Average and Diluted) stood at -$24.33 in 2021, then soared by 80.72% to -$4.69 in 2022, then tumbled by 11945.63% to -$564.94 in 2023, then soared by 99.79% to -$1.2 in 2024, then soared by 87.47% to -$0.15 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.15 in Q3 2025, compared to $22.86 in Q2 2025 and -$23.95 in Q1 2025.